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During gestation, many different mechanisms act to render the maternal immune system tolerant to semi-allogeneic trophoblast
cells of foetal origin, including those mediated via mucins that are expressed during the peri-implantation period in the uterus.
Tumour- associated glycoprotein-72 (TAG-72) enhances the already established tolerogenic features of decidual dendritic cells
with the inability to progress towardsTh1 immune orientation due to lowered interferon (IFN)-𝛾 and interleukin (IL)-15 expression.
Mucine 1 (Muc 1) supports alternative activation of decidual macrophages, restricts the proliferation of decidual regulatory CD56+
bright natural killer (NK) cells, and downregulates their cytotoxic potential, including cytotoxic mediator protein expression.
Removing TAG-72 and Muc 1 from the eutopic implantation site likely contributes to better control of trophoblast invasion by
T cells and NK cells and appears to have important immunologic advantages for successful implantation, in addition to mechanical
advantages. However, these processes may lead to uncontrolled trophoblast growth after implantation, inefficient defence against
infection or tumours, and elimination of unwanted immunocompetent cells at the maternal-foetal interface. The use of mucins by
tumour cells to affect the local microenvironment in order to avoid the host immune response and to promote local tumour growth,
invasion, and metastasis confirms this postulation.
1. Introduction
The mother and conceptus are engaged in a chemical con-
versation throughout pregnancy [1]. Cycling endometrium
provides a microenvironment in which molecules secreted
by uterine cells, including glycoproteins mucin-1- (Muc 1-)
and tumour-associated glycoprotein-72 (TAG-72), are trans-
ported into the uterine lumen, where they represent his-
totrophs required for blastocyst growth and development [2].
An active embryonic stimulus is required to initiate implanta-
tion in terms of the removal of epithelial surface glycoproteins
fromdirectly beneath the implantation site [2].The blastocyst
forms directly under uterine influence after its apposition
and adhesion to the receptive endometrium [2, 3]. Cytokines,
chemokines, and growth factors expressed by decidual cells,
with their pleiotropic and redundant functions, are broadly
involved in stimulating growth, differentiation, and the func-
tion of uterine and trophoblast cells, as well as in their
mutual coordination and synchronization [2, 4]. Blois et al.
[5] showed that pregnancy-specific glycoproteins influence
trophoblast immune evasion. Additionally, angiogenesis in
mice and its predictive value for the pregnancy outcome
have been considered [5]. Recently, the broad and complex
role(s) of Muc 1 and TAG-72 was evaluated at the maternal-
foetal interface at the beginning of pregnancy, when the
dynamic exchange of cytokine orientationswas indispensable
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for immunoadherence [6]. However, many studies in animal
and human models failed to completely elucidate mucin-
mediated immunophysiological and immunopathological
pathways involved in establishing pregnancy.
2. Alloreactivity at
the Maternal-Foetal Interface
During gestation, many different mechanisms act to render
thematernal immune system tolerant to the foetus. Induction
of the adaptive immune response of an allograft begins with
the recognition of the alloantigen by the mother’s T cells.
This generally occurs through 3main processes, including the
direct, indirect, and semidirect pathways, depending on the
antigen presented within major histocompatibility complex
(MHC) molecules [7]. However, “the first signal” by itself
induces T-cell anergy, which is followed by an active immune
response, representing immunomodulation in the absence of
“the second signal” [8]. The second signal represents engage-
ment of costimulatory molecules on antigen-presenting cells
(APCs) with CD28 or CTLA4 on the surface of T cells, allow-
ing selective, activating, or inhibiting T-cell responses [8].
As the second signal providers, decidual dendritic cells (DCs)
as well as macrophages play very important roles in immune
adjustment during pregnancy [9, 10].Human early pregnancy
decidua harbours primarily myeloid mature CD83+ DCs [11],
a very small population of intermediate CD205+DCs [12] and
CD1a+ cells [11, 13]. In humans, the number of mature CD83+
cells decreases during early pregnancy compared to that in
the late secretory phase, whereas immature CD209+ DCs
dominate in the decidua [14, 15]. Decidual T cells are hypore-
active to trophoblast alloantigens [16], possibly because of
their interaction with cognate immune DCs. Therefore, it
has been hypothesized that antigen presentation by immature
DCs induces tolerance, whereas antigen presentation by
mature DCs induces immunity [17, 18]. However, mature
decidual DCs induce CD4+ T-cell tolerance in mice [19].
Lung tissue-specific DCs under steady-state conditions are
sufficiently mature to express intermediate levels of MHC
class II and costimulatory molecules, but these cells polarize
T cells towards the Th2 helper pathway [20].
Thus, the assumption that different maturation states or
different subsets have varying tolerogenic functions can no
longer be used to distinguish between the tolerogenic and
immunogenic properties of DCs [21]. Additionally, freshly
isolated humanmyeloic decidualmatureDCs show a reduced
capacity to produce IL-12 p70 compared to peripheral blood
DCs [22]. Na¨ıve allogeneic human CD4+ T cells primed
with these DCs led to a higher percentage of Th2 cells
than peripheral myeloid DCs [22]. However, the assump-
tion that decidual DCs have tolerogenic functions must
be further investigated because natural killer (NK) cells
and macrophages may stimulate DCs to secrete IL12 and
may cause further induction of Th1 cytokine production
by lymphocytes, resulting in apoptosis of trophoblast cells
and a Th1-type immune bias of abortion [23]. This finding
strongly suggests that the microenvironment is a potent, or
perhaps the most important, modulator of DC function [24],
but the substances responsible for these actions, including
mucins, remain to be elucidated.
3. Accessory Regulators of Alloreactivity
Distinct profiles of cytokine and chemokine secretion by
appropriately stimulated DCs induce and orientate T cells
[25], representing “the third signal” in T-cell activation. DCs
use T-cell-mediated responses by stimulating “na¨ıve” T cells
via the Th2-promoting cytokine IL-10 to induce tolerance
at the maternal-foetal interface and via the Th1-promoting
cytokine IL-12 to stimulate T-cell activity [10], in the absence
of appropriate tolerogenic stimuli. Prostaglandin E2, sup-
ported by progesterone, polarizes the maturation of myeloid
DCs into Th2-promoting DCs, and transforming growth
factor beta promotes tolerogenic DCs [26]. Both mediators
are present at the maternal-foetal interface during normal
pregnancy and may be utilized by DCs to regulate decidual
health. Progesterone enhances the expression of leukaemia
inhibitory factor (LIF) [27], which is one of the most
important factors involved in fertilization and implantation
[28]. In humans,maximum expression of LIF occurs between
19 and 25 days of the menstrual cycle, corresponding to the
opening of the “implantation window” [2]. However, signifi-
cant thinning of the glycoprotein layer (glycocalyx) beneath
the trophoblast implantation site, including disappearance
of its constituent Muc 1, is indispensable for successful
implantation in many species [29]. Muc 1 acts as a physical
barrier between the cell surface and external environment,
thus protecting cells from microorganisms, toxins, or pro-
teolytic factors, as well as preventing trophoblast invasion
with equal efficiency [30, 31]. We recently demonstrated the
absence of tumour-associated TAG-72 in uterine decidua of
normal and pathological human pregnancies (nonembryonic
pregnancy and missed abortion) at the implantation sites
although TAG-72 was present in epithelial cells at and away
from the tubal implantation site of an ectopic pregnancy
[32]. Moreover, our recent in vitro studies confirmed the
interaction between Muc 1 [33] and TAG-72 [32] with APCs
at the maternal-foetal interface [32]. Our experiments sug-
gested that they participate in the maturation of CD1a+ DCs
and macrophages and critically influence their phenotype,
cytokine and chemokine production, and functions, as shown
in Figure 1(a). This method of controlling immune reactions,
including trophoblastic invasion, occurs at the maternal-
foetal interface [34].
4. Regulation of Mucin Expression
Mucins are a family of heavily glycosylated proteins [35].
Numerous groups of transmembrane mucins include Muc 1,
which harbours a transmembrane domain, a short cytoplas-
mic tail, and an extensive extracellular domain [33]. Mucins
are ubiquitously present in diverse mucous membranes and
are localized at the apical surface of polarized epithelial cells
in the lungs, stomach, intestines, and eyes [36, 37].
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Figure 1: Proposed model for antigen-presenting cells and decidual lymphocytes interactions at the maternal-foetal interface in the presence
(a) and absence (b) of mucin-1- (Muc 1-) and tumour-associated glycoprotein-72 (TAG-72). The functions of dendritic cells (DCs) and
macrophages (Mfgs) may be influenced by Muc 1 and TAG-72 that bind to the mannose receptor (MR) and CD209. TAG-72-shaped DCs
may produce less CD83, resulting in lower proliferation and selective apoptosis of cognate cytotoxic T cells to allow survival of Th2-oriented
T cells with low production of IFN-gamma (IFN-𝛾), attracted by CC chemokine ligand- (CCL-)19 and CCL22. Mfgs in the presence of TAG-
72 produced higher levels of interleukin (IL)-10 and IL-1 receptor antagonist (IL-1RA), but significantly decreased levels of IL-12 and CCL3,
support aTh2bias.Muc 1-shapedMfgs increased IL-1 receptor type II (IL-1R type II) expression, whereas aD6decoy, CD80, CD86, and human
leukocyte antigen (HLA)DR remain relatively unchanged. Muc 1-shapedMfgs and TAG-72-treated DCs appear to decrease IL-15 production
and cannot support the proliferation of CD56 bright NK cells and expression of cytotoxic mediators. Low IFN-𝛾 expression by TAG-treated
DCs does not support decidual vessel remodelling. During normal eutopic implantation, removing surface epithelial glycoproteins (b) allows
antigen-presenting cells to supportmild proinflammatory reactions by increasing IL-15 and IFN-𝛾 production and amplifyingNK cells, which
are rich in cytotoxic mediators.
Most studies examining the role of mucins in reproduc-
tion have focused on human Muc 1 because of its pre-
dominant expression in the human endometrium [38]. Muc
1 is present at the apical surface of epithelial cells in the
endometrium throughout the menstrual cycle [39]. Human
Muc 1 expression is high during the peri-implantation period
[40]. It is likely the first molecule that the embryo encounters
before adhering to the endometrium [30, 41] (Figure 1(a)).
In the uterus, Muc 1 suppresses the interaction between
the implanting embryo and maternal endometrial adhesion
molecules, thus creating a barrier to implantation in humans
[30] as well as many other mammalian species [31]. This
theory has been confirmed by experimental data that show
that mice lacking the gene for Muc-1 have a persistently
receptive endometrium [38, 42]. Its removal is necessary
for successful implantation in humans [43]. Indeed, Muc-
1 is not present beneath the embryo implantation site [29,
30]. It is thought that embryos send paracrine signals and
participate in Muc-1 clearance [43]. Muc 1 may participate in
selectin-dependent interactions in the uterus, thus promoting
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cell-cell interactions in some contexts [44]. Muc 1 can be
also removed from the site of implantation because of
paracrine signals from local milieu [43], including different
bacterial and viral products [45]. It could be overexpressed
by hypoxia at the maternal-foetal interface and contributes
to hypoxia-driven angiogenesis, as it was seen previously in
the pancreatic cancer cells [46]. TNF-𝛼 is a cytokine secreted
by endometrium and blastocyst, which probably mediated
binding of nuclear factor kappa 𝛽 to its binding site in the
promoter of Muc-1 gene [45]. On the other hand, TNF-𝛼
leads to the removal of Muc-1 in human uterine epithelial
cells by increasing expression of sheddase TACE (tumour
necrosis factor-alpha-converting enzyme)/ADAM17 (a dis-
integrin and metalloprotease-like 17) [47]. Membrane-type
matrix metalloprotease (MT1-MMP) also contributes elim-
inating the external part of Muc-1 molecule independently
of TACE/ADAM17, and its expression increases during the
receptive phase in the endometrial biopsy [48]. Furthermore,
immunohistochemistry demonstrated the colocalization of
MUC-1 and MT1-MMP in human uterine epithelium during
implantation [48].
Moreover, Muc 1 is transcriptionally regulated by oestro-
gen, progesterone, and glucocorticoids [49, 50]. Sex hor-
mones control gene transcription of Muc 1 either by direct
interaction with the Muc 1 promoter or indirectly by stimu-
lating or suppressing other transcription factors in the uterus
[49]. Progesterone increases the synthesis and secretion of
Muc 1 at the systemic level during early pregnancy, but
cells—both beneath and immediately adjacent to attached
embryos—do not contain detectable levels of Muc 1, whereas
the cells further away in the epithelial layer remain unaffected
[49, 50]. Uterine tissuemacrophage-derived factors (LIF) and
cytokines (IL-1𝛽) promote uterine receptivity by regulating
surface glycan structures in epithelial cells [51]. Furthermore,
Shyu et al. showed thatMuc 1mRNA andMuc 1 protein levels
increase with gestational stage during human pregnancy, pri-
marily because of Muc 1 expression of trophoblast cells [52].
Osteen et al. observed TAG-72 in the normal postovu-
latory, secretory phase endometrium, but not in the prolif-
erative phase [53]. TAG-72+ cells were rarely observed in the
lower uterine segment using immunohistochemistry [53].We
recently showed that TAG-72 was not present in the decidual
tissue of healthy and eutopic pathological early pregnancies,
including missed abortion and blighted ovum [54]. In
contrast, TAG-72was present in the tubalmucosa at and away
from the implantation site during ectopic tubal pregnancy,
but not in the uterine mucosa of the same woman [54]. To
our knowledge, in the recent scientific literature there is little
data that speaks about TAG-72 regulation; however, TAG-72
appears to be hormonally dependent. Estradiol can inhibit
TAG-72 expression, whereas progesterone does not directly
stimulate TAG-72 [55]. Additionally, TAG-72 downregulates
oestrogen and progesterone receptors in endometriotic
lesions [55]. Both autocrine and paracrine mechanisms are
involved in regulating TAG-72 expression [56].
Glycoproteins, Muc 1 [30, 40] and TAG-72 [53, 54], are
present in peri-implantation period in uterus and participate
certainly in highly controlled process of trophoblast invasion,
which resembles tumor invasion by deep decidual inva-
sion, modifying of cellular morphology, and an epithelial-
to-mesenchymal transition [3, 57]. Muc 1 overexpression
suppresses extravilious trophoblast invasionmainly via mod-
ulating 𝛽1-integrin signaling in severe preeclamptic placentas
[58]. 𝛽1-integrin-silenced cells show a defective activation
of the epidermal growth factor receptor-signaling cascade,
leading to decreased in vitro proliferation, impaired migra-
tion, and invasive behavior [58]. However, the modification
of cellular glycosylation is a common phenotypic change of
cancer cells that mainly affects the outer part of glycans,
leading to the expression of tumour-associated carbohydrate
antigens [59]. The transmembrane mucins, in particular, are
overexpressed and aberrantly glycosylated in most cases of
adenocarcinoma and are also associated with constitutive
activation of a growth factor signalling, invasive proliferation
of tumors, possibility of metastatic spread, and activation of
a programme of tumor cell repair and survival (immortality)
[3, 59].The tumormucins interact with monocytes, dendritic
cells, and T and NK cells supporting anti-inflammatory and
tolerogenic immune response toward tumor cells, favoring
in that way the tumor growth with a patient’s poor outcome
[3, 59].
5. Mucins Suppress Alloreactivity at
the Maternal-Foetal Interface
Trophoblast cells express mucins throughout gestation and
thereby contribute to increased mucin concentrations at the
maternal-foetal interface during pregnancy [60]. Whether
Muc 1 affects decidual NK and T-cell functions during later
pregnancy is unknown. In vitro Muc 1 competes with the
PAM-1 monoclonal antibody, which is directed towards the
carbohydrate recognition domain of the mannose receptor
(MR) [25], followed by binding and internalization of MR
in early decidual CD14+ cells in a dose-dependent manner
[33]. This finding presents a possible mechanism for Muc
1 to influence the phenotype and functional properties of
decidual CD14+ cells in in vivo, as illustrated in Figure 1(a).
In in vitro experiments, Muc 1 stimulated macrophages to
increase the surface expression of IL1-R type II (Figure 1(a)),
which binds to IL-1 but does not transduce signals in the cell,
quenching the IL-1 proinflammatory signal [61]. In contrast,
a D6 decoy for proinflammatory chemokines, as well as cos-
timulatory CD80 and CD86 molecules, HLA-DR and CD83,
remains relatively unchanged after Muc 1 stimulation [33].
Muc 1 significantly decreases IL-15 in decidual macrophages,
whereas IFN-𝛾, IL-18, IL-10, CCL3, and CCL17 are essentially
unchanged [33].
Immature decidual CD1a+ cells express CD209 [15] and a
high number of MRs on the surface of single cells [62]. MR
contains 8 and CD209 contains 7 extracellular carbohydrate
recognition domains [63], indicating that these cells can
bind to highly glycosylated molecules such as TAG-72 [64]
(Figure 1(a)). Indeed, TAG-72 competes with mannan, which
is a primordial ligand for the carbohydrate recognition
domain [64], and it binds MR and CD209 on decidual
CD1a+ cells in vitro [32]. This binding is important because
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ligands binding the carbohydrate recognition domain of
MR can activate an anti-inflammatory and a tolerogenic
response in monocyte-derived DCs [25] such as decidual
DCs [32]. Indeed, after TAG-72 stimulation, decidual CD1a+
cells show significantly decreased CD83molecules, likely due
to its active secretion [65]. CD83 molecules have tolerogenic
properties owing to the significantly reduced DC-mediated
T-cell stimulation [65], which may contribute to immune
tolerance at the maternal-foetal interface in the presence of
TAG-72 (Figure 1(a)).
6. Effects of Mucins on Decidual
T-Cell Functions
Hiltbold et al. showed that DCs present various glycosylated
or nonglycosylated forms of Muc 1 using MHC class I
molecules [66].The efficiency of processing and the resulting
strength of CD8+ T-cell activities inversely correlated with
the degree of glycosylation of the antigen [66]. Agrawal et
al. also suggested that Muc-1-derived peptides are processed
and presented in the context of MHC class I molecules on the
surface of tumour cells [67]. CD8+ T cells could detect Muc
1 peptides associated with MHC class I. Most Muc 1 epitopes
did not contain a consensus motif for a particular MHC class
I allele and bound with low “affinity,” compared with known
high-affinity peptides [68]. MHC-restricted antigen recogni-
tion of mucins indicates that a given T-cell will recognize a
peptide antigen only when it is bound to a host body’s self-
MHC molecule [68]. Normally, T cells are stimulated only
in the presence of self-MHC molecules; hence, the antigen
is recognized only when peptides are bound to these self-
MHC molecules. At the maternal-foetal interface, CD8+ T-
cells are nearly depleted [68].Magarian-Blander et al. showed
that direct recognition of theMuc 1 peptide epitope by a T-cell
receptor in the absence of presentation by MHCs induces a
partial signal that is completed by further interactions with
other receptor/ligand pairs on the surface of the CTL and
their target cells [69].
TAG-72-treated decidual CD1a+ cells were unable to
stimulate the proliferation of syngeneic decidual T cells [32],
mostly of the CD45+ phenotype [70] (Figure 1(a)), although
they significantly stimulated the proliferation of allogeneic,
na¨ıve cord blood T cells [32]. Furthermore, allogeneic T-cells
coculturedwithmonocyte-derivedDCs,whichwerematured
using an antimannose receptor monoclonal antibody of the
PAM-1 clone in vitro, initially proliferated but later became
anergic and behaved as suppressor/regulatory cells [25].Thus,
poor proliferation that is observed upon rechallenge with
cognate TAG-72-treated CD1a+ DCs suggests some degree of
decidual T-cell tolerance. This finding agrees with the previ-
ous finding that TAG-72-treated CD1a+ cells decreased CD83
expression, which is considered a DC-activation marker [32]
and is responsible for specific support of the expansion of
newly primed na¨ıve CD8+ T-cells and long-term survival
of antigen-specific T cells by inducing proliferation and
inhibiting apoptosis [71].
Furthermore, TAG-72-treated CD1a+ cells decreased
IFN-𝛾 production in syngeneic decidual and allogeneic cord
blood T cells, even in the presence of lipopolysaccharide
(LPS) [32] (Figure 1(a)). However, IL-4 is not likely to be
increased in decidual T cells after close contact with TAG-
72-primed CD1a+ DCs [32]. However, intracellular IL-4
expression was increased in allogeneic cord blood T cells,
even in the presence of TAG-72 and LPS pretreated CD1a+
cells [32]. This powerful tolerogenic feature of TAG-72 is not
observed in freshly isolated decidual T cells, which appear to
be oriented towards the Th2 pathway.
Accordingly, PAM-1-treated monocyte-derived DCs
could not polarizeTh1 effector cells and did not secrete proin-
flammatory chemokines, CXCL10 and CCL19 [25]. In con-
trast, they produced large amounts of anti-inflammatory
CCL22 and CCL17 chemokines [72]. These findings empha-
size the anti-inflammatory properties of CD1a+ cells treated
with ligands for the carbohydrate recognition domain, partic-
ularly TAG-72, in terms of its interaction with T cells. Addi-
tionally, mucins can potentiate selective survival of na¨ıve T
cells, which may be modified using mucins [39].
7. Effects of Mucins on Decidual NK
Cell Functions
The addition of Muc 1 in a suspension of decidual mononu-
clear cells substantially reduced the percentage of IL-15- and
IFN-𝛾-expressing CD14+ cells [33], as illustrated in Figure 1.
Through contact withMUC-1-treatedmacrophages, decidual
cognate NK cells proliferated less efficiently and showed
significantly decreased expression of perforin, Fas Ligand,
and tumour necrosis factor-related apoptosis-inducing lig-
and (TRAIL) based on decreased IL-15 levels in decidual
CD14+ cells in the presence ofMUC 1 [33] (Figure 1(a)).These
NK cells are likely inefficient in the control of trophoblast
invasion owing to their low numbers and weak cytotoxic
potential. However, in the presence of Muc 1, trophoblast
invasion does not occur at the eutopic implantation site. At
the implantation site in tubal ectopic pregnancy, TAG-72 is
present and appears to disturb trophoblast growth control
because of diminished intracellular IL-15 and IFN-𝛾 cytokine
production in DCs [32]. The lower proportion of IL-15-
expressing CD1a+ DCs isolated from the tubal implantation
site than that isolated from the lining of the uterus of the
same woman [32] supports the hypothesis and may explain
deeper trophoblast invasion in the tubal wall during ectopic
pregnancy; this may also be themain reason for tubal rupture
and tubal pregnancy termination [73]. Similarly, tumour-
associated macrophages isolated from human ovarian cancer
express MR, which can bind TAG-72 to modulate cytokine
production towards an unwanted immune-suppressive pro-
file with an increased IL-10, not IL-12, and decreased
Th1-attracting chemokine CCL3 expression [74]. Further-
more, TAG-72 inhibits lipopolysaccharide-mediated intracel-
lular signalling cascades in tumour-associated macrophages
induced by infection, leading the orientation of T cells
with no experience, toward a Th2 response [75]. This result
suggests a mechanism of alternative activation, which allows
faster tumour progression by promoting tumour cell inva-
sion, migration, and metastasis [75]. It may also explain why
6 Clinical and Developmental Immunology
higher expression of TAG-72 occurs in tumour tissues during
advanced tumour stages compared to early stages in ovarian
[76], breast [77], and gastric [78] tumours.
In the absence of tolerogenic mucin stimulation [25, 79]
at the eutopic implantation site, DCs appear to support mild
proinflammatory reactions through IL-15 and IFN-𝛾 produc-
tion [32], as shown in Figure 1(b). IL-15-shaped decidual NK
cells allow trophoblast infiltration during normal pregnancy,
but they can also kill these cells in the presence of IL-
15, causing termination of pregnancy [80], likely through
perforin- and granulysin-mediated cell killing involving the
necrotic and apoptotic pathways [81]. Perforin and granulysin
expression is abundant in freshly isolated normal human
decidual NK cells [82]. These apoptotic molecules can be
upregulated upon cocultivation with DCs and macrophages
[83], which are the main sources of IL-15. Decidual NK cells
proliferate and secrete more IFN-𝛾, which plays critical roles
in angiogenesis, immunemodulation at the implantation site,
and maintenance of the decidual (maternal) component of
the placenta [84].
8. Conclusion
During pregnancy inmammalianmaternal tissues, immuno-
competent cells are in direct and intimate contact with tro-
phoblast cells of the foetoplacental unit. Successful survival
of the foetal allograft can be explained using numerous
immunoregulatorymechanisms acting at thematernal-foetal
interface. According to our data, the main roles of Muc
1 and TAG-72 include regulation of maturation as well
as expression of chemokines and cytokines by decidual
APCs. Their effects are primarily mediated by C-type lectin
endocytic receptors (CD209 and MR), which direct Th2
immune responses and alternative activation of APCs [85].
Thus, decidual mucins restrain strong anti-inflammatory
local milieu. Similarly, studies examining tumour models
have shown thatmucin overexpression, aberrant intracellular
localization, and changes in glycosylation are consistently
associated with stronger invasion [86]. The removal of
mucins during the first trimester of pregnancy is necessary
to create a moderate “inflammatory” microenvironment,
successful implantation, and tissue remodelling.
Acknowledgment
This investigation was supported by the Croatian Ministry of
Science, Education and Sports, Grant no. 0620402-0376 to D.
Rukavina and Grant no. 0620402-0377 to G. Laskarin.
References
[1] O. B. Christiansen, H. S. Nielsen, and A. M. Kolte, “Inflamma-
tion andmiscarriage,” Seminars in Fetal and Neonatal Medicine,
vol. 11, no. 5, pp. 302–308, 2006.
[2] N. Dekel, Y. Gnainsky, I. Granot, and G. Mor, “Inflammation
and implantation,” American Journal of Reproductive Immunol-
ogy, vol. 63, no. 1, pp. 17–21, 2010.
[3] L. Serman and A. Serman, “The role of glycoproteins in
the processes of implantation and placentation,” Gynaecologia
et Perinatologia, vol. 15, pp. 82–88, 2006.
[4] D. Rukavina and G. Vince, “Roles of cytokines and immune
cells at the interface—a workshop report,” Placenta, vol. 21, no.
1, supplement A, pp. S97–S98, 2000.
[5] S. M. Blois, B. F. Klapp, and G. Barrientos, “Decidualization and
angiogenesis in early pregnancy: unravelling the functions of
DC and NK cells,” Journal of Reproductive Immunology, vol. 88,
no. 2, pp. 86–92, 2011.
[6] G. Laskarin, K. Cupurdija, V. Sotosek Tokmadzic et al., “The
presence of functionalmannose receptor onmacrophages at the
maternal-fetal interface,” Human Reproduction, vol. 20, no. 4,
pp. 1057–1066, 2005.
[7] J. K. Archbold, L. K. Ely, L. Kjer-Nielsen et al., “T cell allorecog-
nition andMHC restriction—a case of Jekyll andHyde?DC and
NK cells,” Journal of Reproductive Immunology, pp. 86–92, 2011.
[8] E. Padovan, G. Casorati, P. Dellabona, C. Giachino, and A.
Lanzavecchia, “Dual receptor T-cells—implications for allore-
activity and autoimmunity,” Annals of the New York Academy of
Sciences, vol. 756, pp. 66–70, 1995.
[9] S. M. Blois, U. Kammerer, C. A. Soto et al., “Dendritic cells: key
to fetal tolerance?” Biology of Reproduction, vol. 77, no. 4, pp.
590–598, 2007.
[10] G. Laskarin, U. Ka¨mmerer, D. Rukavina, A. W. Thomson,
N. Fernandez, and S. M. Blois, “Antigen-presenting cells and
materno-fetal tolerance: an emerging role for dendritic cells,”
American Journal of Reproductive Immunology, vol. 58, no. 3, pp.
255–267, 2007.
[11] U. Kammerer, M. Schoppet, A. D. McLellan et al., “Human
decidua contains potent immunostimulatory CD83+ dendritic
cells,” American Journal of Pathology, vol. 157, no. 1, pp. 159–169,
2000.
[12] L. Gardner and A. Moffett, “Dendritic cells in the human
decidua,” Biology of Reproduction, vol. 69, no. 4, pp. 1438–1446,
2003.
[13] G. Laskarin, A. Redzovic´, Z. Rubesa et al., “Decidual natural
killer cell tuning by autologous dendritic cells,” American
Journal of Reproductive Immunology, vol. 59, no. 5, pp. 433–445,
2008.
[14] L. Rieger, A. Honig,M. Su¨tterlin et al., “Antigen-presenting cells
in human endometrium during the menstrual cycle compared
to early pregnancy,” Journal of the Society for Gynecologic
Investigation, vol. 11, no. 7, pp. 488–493, 2004.
[15] U. Ka¨mmerer, A. O. Eggert, M. Kapp et al., “Unique appearance
of proliferating antigen-presenting cells expressing DC-SIGN
(CD209) in the decidua of early human pregnancy,” American
Journal of Pathology, vol. 162, no. 3, pp. 887–896, 2003.
[16] S. Verma, S. E. Hiby, Y.W. Loke, and A. King, “Human decidual
natural killer cells express the receptor for and respond to the
cytokine interleukin 15,” Biology of Reproduction, vol. 62, no. 4,
pp. 959–968, 2000.
[17] M. V. Dhodapkar, J. W. Young, P. B. Chapman et al., “Paucity
of functional T-cell memory to melanoma antigens in healthy
donors and melanoma patients,” Clinical Cancer Research, vol.
6, no. 12, pp. 4831–4838, 2000.
[18] R. M. Steinman, “Dendritic cells and the control of immunity:
enhancing the efficiency of antigen presentation,” Mount Sinai
Journal of Medicine, vol. 68, no. 3, pp. 160–166, 2001.
Clinical and Developmental Immunology 7
[19] O. Akbari, R. H. DeKruyff, and D. T. Umetsu, “Pulmonary
dendritic cells producing IL-10 mediate tolerance induced by
respiratory exposure to antigen,”Nature Immunology, vol. 2, no.
8, pp. 725–731, 2001.
[20] R. M. Steinman, “Some interfaces of dendritic cell biology,”
APMIS, vol. 111, no. 7-8, pp. 675–697, 2003.
[21] N. Cools, P. Ponsaerts, V. F. I. van Tendeloo, and Z. N. Berne-
man, “Balancing between immunity and tolerance: an inter-
play between dendritic cells, regulatory T cells, and effector T
cells,” Journal of Leukocyte Biology, vol. 82, no. 6, pp. 1365–1374,
2007.
[22] S. Miyazaki, H. Tsuda, M. Sakai et al., “Predominance of Th2-
promoting dendritic cells in early human pregnancy decidua,”
Journal of Leukocyte Biology, vol. 74, no. 4, pp. 514–522, 2003.
[23] S. M. Blois, C. D. A. Soto, M. Tometten, B. F. Klapp, R. A.
Margni, and P. C. Arck, “Lineage, maturity, and phenotype of
uterine murine dendritic cells throughout gestation indicate a
protective role in maintaining pregnancy,” Biology of Reproduc-
tion, vol. 70, no. 4, pp. 1018–1023, 2004.
[24] B. Pulendran, “Immune activation: death, danger and dendritic
cells,” Current Biology, vol. 14, no. 1, pp. R30–R32, 2004.
[25] M. Chieppa, G. Bianchi, A. Doni et al., “Cross-linking of
the mannose receptor on monocyte-derived dendritic cells
activates an anti-inflammatory immunosuppressive program,”
Journal of Immunology, vol. 171, no. 9, pp. 4552–4560, 2003.
[26] P. Kalin´ski, C. M. U. Hilkens, A. Snijders, F. G. M. Snijdewint,
and M. L. Kapsenberg, “Dendritic cells, obtained from periph-
eral blood precursors in the presence of PGE2, promote Th2
responses,”Advances in ExperimentalMedicine and Biology, vol.
417, pp. 363–367, 1997.
[27] M.-P. Piccinni, “Role of T-cell cytokines in decidua and in
cumulus oophorus during pregnancy,” Gynecologic and Obstet-
ric Investigation, vol. 64, no. 3, pp. 144–148, 2007.
[28] E. B. Cullinan, S. J. Abbondanzo, P. S. Anderson, J.W. Pollard, B.
A. Lessey, and C. L. Stewart, “Leukemia inhibitory factor (LIF)
and LIF receptor expression in human endometrium suggests
a potential autocrine/paracrine function in regulating embryo
implantation,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 93, no. 7, pp. 3115–3120, 1996.
[29] J. D. Aplin, “MUC-1 glycosylation in endometrium: possible
roles of the apical glycocalyx at implantation,” Human Repro-
duction, vol. 14, supplement 2, pp. 17–25, 1999.
[30] J. D. Aplin, “Embryo implantation: the molecular mechanism
remains elusive,” Reproductive BioMedicine Online, vol. 13, no.
6, pp. 833–839, 2006.
[31] M. Brayman, A. Thathiah, and D. D. Carson, “MUC1: a multi-
functional cell surface component of reproductive tissue epithe-
lia,”Reproductive Biology and Endocrinology, vol. 2, article no. 4,
2004.
[32] G. Laskarin, A. Redzovic, I. Vlastelic et al., “Tumor-associated
glycoprotein (TAG-72) is a natural ligand for the C-type lectin-
like domain that induces anti-inflammatory orientation of
early pregnancy decidual CD1a+ dendritic cells,” Journal of
Reproductive Immunology, vol. 88, no. 1, pp. 12–23, 2011.
[33] G. Laskarin, S. S. Medancic, A. Redzovic, D. Duric, and D.
Rukavina, “Specific decidual CD14(+) cells hamper cognate NK
cell proliferation and cytolytic mediator expression after mucin
1 treatment in vitro,” Journal of Reproductive Immunology, vol.
95, pp. 36–45, 2012.
[34] G. Laskarin, A. Redzovic, S. Srsen Medancic, and D. Rukav-
ina, “Regulation of NK-cell function by mucins via antigen-
presenting cells,”Medical Hypotheses, vol. 75, no. 6, pp. 541–543,
2010.
[35] M. Brayman, A. Thathiah, and D. D. Carson, “MUC1: a multi-
functional cell surface component of reproductive tissue epithe-
lia,” Reproductive Biology and Endocrinology, vol. 2, article 4,
2004.
[36] S. Rachagani, M. P. Torres, N. Moniaux, and S. K. Batra,
“Current status of mucins in the diagnosis and therapy of
cancer,” BioFactors, vol. 35, no. 6, pp. 509–527, 2009.
[37] Y. H. Sheng, S. Z. Hasnain, T. H. J. Florin, andM. A.McGuckin,
“Mucins in inflammatory bowel diseases and colorectal cancer,”
Journal of Gastroenterology andHepatology, vol. 27, no. 1, pp. 28–
38, 2012.
[38] N. Dharmaraj, S. J. Gendler, and D. D. Carson, “Expression of
human MUC1 during early pregnancy in the human MUC1
transgenic mouse model,” Biology of Reproduction, vol. 81, no.
6, pp. 1182–1188, 2009.
[39] D.D. Carson, “The cytoplasmic tail ofMUC1: a very busy place,”
Science Signaling, vol. 1, no. 27, article pe35, 2008.
[40] C. L. Hattrup and S. J. Gendler, “Structure and function of the
cell surface (tethered) mucins,” Annual Review of Physiology,
vol. 70, pp. 431–457, 2008.
[41] B. Refaat, H. Simpson, E. Britton et al., “Why does the fallopian
tube fail in ectopic pregnancy? the role of activins, inducible
nitric oxide synthase, and MUC1 in ectopic implantation,”
Fertility and Sterility, vol. 97, no. 5, pp. 1115–1123, 2012.
[42] E. Lacunza, V. Ferretti, C. Barbeito, A. Segal-Eiras, and M.
V. Croce, “Immunohistochemical evidence of Muc1 expression
during rat embryonic development,” European Journal of Histo-
chemistry, vol. 54, no. 4, article e49, 2010.
[43] A. Sharma and P. Kumar, “Understanding implantation win-
dow, a crucial phenomenon,” Journal of Human Reproductive
Sciences, vol. 5, pp. 2–6, 2012.
[44] D. D. Carson, J. Julian, B. A. Lessey, A. Prakobphol, and S. J.
Fisher, “MUC1 is a scaffold for selectin ligands in the human
uterus,” Frontiers in Bioscience, vol. 11, no. 3, pp. 2903–2908,
2006.
[45] A. L. Radtke, A. J. Quayle, andM.M.Herbst-Kralovetz, “Micro-
bial products alter the expression of membrane-associated
mucin and antimicrobial peptides in a three-dimensional
human endocervical epithelial cell model,” Biology of Reproduc-
tion, vol. 87, article 132, 2012.
[46] S. Kitamoto, S. Yokoyama,M.Higashi, N. Yamada, S. Takao, and
S. Yonezawa, “MUC1 enhances hypoxia-driven angiogenesis
through the regulation of multiple proangiogenic factors,”
Oncogene, 2013.
[47] A. Thathiah, C. P. Blobel, and D. D. Carson, “Tumor necrosis
factor-𝛼 converting enzyme/ADAM 17 mediates MUC1 shed-
ding,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 3386–
3394, 2003.
[48] A. Thathiah and D. D. Carson, “MT1-MMP mediates MUC1
shedding independent of TACE/ADAM17,” Biochemical Jour-
nal, vol. 382, no. 1, pp. 363–373, 2004.
[49] M. Meseguer, J. D. Aplin, P. Caballero-Campo et al., “Human
endometrial mucin MUC1 is up-regulated by progesterone and
down-regulated in vitro by the human blastocyst,” Biology of
Reproduction, vol. 64, no. 2, pp. 590–601, 2001.
8 Clinical and Developmental Immunology
[50] N. Dharmaraj, P. Wang, and D. D. Carson, “Cytokine and
progesterone receptor interplay in the regulation ofMUC1 gene
expression,”Molecular Endocrinology, vol. 24, no. 12, pp. 2253–
2266, 2010.
[51] M. J. Jasper, A. S. Care, B. Sullivan, W. V. Ingman, J. D. Aplin,
and S. A. Robertson, “Macrophage-derived LIF and IL1B regu-
late alpha(1,2)fucosyltransferase 2 (Fut2) expression in mouse
uterine epithelial cells during early pregnancy,” Biology of
Reproduction, vol. 84, no. 1, pp. 179–188, 2011.
[52] M.-K. Shyu, M.-C. Lin, C.-H. Liu et al., “MUC1 expression is
increased during human placental development and suppresses
trophoblast-like cell invasion in vitro,” Biology of Reproduction,
vol. 79, no. 2, pp. 233–239, 2008.
[53] K. G. Osteen, T. L. Anderson, K. Schwartz, J. T. Hargrove, and
F. Gorstein, “Distribution of tumor-associated glycoprotein-72
(TAG-72) expression throughout the normal female reproduc-
tive tract,” International Journal of Gynecological Pathology, vol.
11, no. 3, pp. 216–220, 1992.
[54] K. G. Osteen, T. L. Anderson, J. T. Hargrove, G. A. Hill, and
F. Gorstein, “Epithelial cells from normal human endometrium
express a tumor-associated glycoprotein (TAG-72) epitope in
vitro,” American Journal of Obstetrics and Gynecology, vol. 163,
no. 2, pp. 478–484, 1990.
[55] B. A. Lessey and J. A. Pindzola, “Tumor-associated glycopro-
tein (TAG-72) in endometriotic implants,” Journal of Clinical
Endocrinology and Metabolism, vol. 76, no. 4, pp. 1075–1079,
1993.
[56] H. E. Cajigas, E. Fariza, R. E. Scully, and A. D. Thor, “Enhance-
ment of tumor-associated glycoprotein-72 antigen expression
in hormone-related ovarian serous borderline tumors,” Cancer,
vol. 68, pp. 348–354, 1991.
[57] A. Sharma and P. Kumar, “Understanding implantation win-
dow, a crucial phenomenon,” Journal of Human Reproductive
Sciences, vol. 5, pp. 2–6, 2012.
[58] M.-K. Shyu, C.-W. Chen, N.-Y. Lin et al., “MUC1 expression
is elevated in severe preeclamptic placentas and suppresses
trophoblast cell invasion via 𝛽1-integrin signaling,” Journal of
Clinical Endocrinology andMetabolism, vol. 96, no. 12, pp. 3759–
3767, 2011.
[59] C. B. Madsen, C. Petersen, K. Lavrsen et al., “Cancer associated
aberrant protein O-glycosylation can modify antigen process-
ing and immune response,” PLoS One, vol. 7, no. 11, Article ID
e50139, 2012.
[60] Z. Bojic´-Trbojevic´, M. J. Krivokuc´a, S. Vrzic´-Petronijevic´, M.
Petronijevic´, and L. Vic´ovac, “Expression of tumor associated
antigens CA 15-3 and CA 19-9 in trophoblast of the normal
human placenta,” European Journal of Gynaecological Oncology,
vol. 33, pp. 281–284, 2012.
[61] F. Re, M. Sironi, M. Muzio et al., “Inhibition of interleukin-
1 responsiveness by type II receptor gene transfer: a surface
“Receptor” with anti-interleukin-1 function,” Journal of Experi-
mental Medicine, vol. 183, no. 4, pp. 1841–1850, 1996.
[62] G. Laskarin, A. Redzovic´, Z. Rubesa et al., “Decidual natural
killer cell tuning by autologous dendritic cells,” American
Journal of Reproductive Immunology, vol. 59, pp. 433–445, 2008.
[63] A. M. Kerrigan and G. D. Brown, “C-type lectins and phagocy-
tosis,” Immunobiology, vol. 214, no. 7, pp. 562–575, 2009.
[64] P. R. Taylor, S. Gordon, and L. Martinez-Pomares, “The man-
nose receptor: linking homeostasis and immunity through
sugar recognition,” Trends in Immunology, vol. 26, no. 2, pp.
104–110, 2005.
[65] Y. Fujimoto and T. F. Tedder, “CD83: a regulatory molecule
of the immune system with great potential for therapeutic
application,” Journal of Medical and Dental Sciences, vol. 53, no.
2, pp. 85–91, 2006.
[66] E. M. Hiltbold, M. D. Alter, P. Ciborowski, and O. J. Finn,
“Presentation ofMUC1 tumor antigen byClass IMHC andCTL
function correlate with the glycosylation state of the protein
taken up by dendritic cells,” Cellular Immunology, vol. 194, no.
2, pp. 143–149, 1999.
[67] B. Agrawal, M. A. Reddish, B. Christian et al., “The anti-MUC1
monoclonal antibody BCP8 can be used to isolate and identify
putative major histocompatibility complex class I associated
amino acid sequences,”Cancer Research, vol. 58, no. 22, pp. 5151–
5156, 1998.
[68] V. Apostolopoulos, J. S. Haurum, and I. F. C. McKenzie, “MUC1
peptide epitopes associated with five different H-2 class I
molecules,” European Journal of Immunology, vol. 27, no. 10, pp.
2579–2587, 1997.
[69] J. Magarian-Blander, P. Ciborowski, S. Hsia, S. C. Watkins,
and O. J. Finn, “Intercellular and intracellular events following
the MHC-unrestricted TCR recognition of a tumor-specific
peptide epitope on the epithelial antigen MUC1,” Journal of
Immunology, vol. 160, no. 7, pp. 3111–3120, 1998.
[70] I. I. Slukvin, A. A. Merkulova, M. A. Vodyanik, and V. P.
Chernyshov, “Differential expression of CD45RA and CD45RO
molecules on human decidual and peripheral blood lym-
phocytes at early stage of pregnancy,” American Journal of
Reproductive Immunology, vol. 35, no. 1, pp. 16–22, 1996.
[71] N. Hirano, M. O. Butler, Z. Xia et al., “Engagement of CD83
ligand induces prolonged expansion of CD8+ T cells and
preferential enrichment for antigen specificity,” Blood, vol. 107,
no. 4, pp. 1528–1536, 2006.
[72] P. Fraticelli, M. Sironi, G. Bianchi et al., “Fractalkine (CX3CL1)
as an amplification circuit of polarized Th1 responses,” Journal
of Clinical Investigation, vol. 107, no. 9, pp. 1173–1181, 2001.
[73] N. Vassiliadou and J. N. Bulmer, “Characterization of tubal and
decidual leukocyte populations in ectopic pregnancy: evidence
that endometrial granulated lymphocytes are absent from the
tubal implantation site,” Fertility and Sterility, vol. 69, no. 4, pp.
760–767, 1998.
[74] P. Monti, B. E. Leone, A. Zerbi et al., “Tumor-derived MUC1
mucins interact with differentiating monocytes and induce IL-
10highIL-12low regulatory dendritic cell,” Journal of Immunol-
ogy, vol. 172, no. 12, pp. 7341–7349, 2004.
[75] P. Allavena, M. Chieppa, G. Bianchi et al., “Engagement of the
Mannose receptor by tumoralmucins activates an immune sup-
pressive phenotype in human tumor-associated macrophages,”
Clinical and Developmental Immunology, vol. 2010, Article ID
547179, 2010.
[76] M. P. Ponnusamy, G. Venkatraman, A. P. Singh et al., “Expres-
sion of TAG-72 in ovarian cancer and its correlation with tumor
stage and patient prognosis,” Cancer Letters, vol. 251, no. 2, pp.
247–257, 2007.
[77] C. Pizzi, A. Sgambato, M. de Laurentiis et al., “TAG-72 expres-
sion and clinical outcome in primary breast cancer,” Oncology
reports, vol. 6, no. 6, pp. 1399–1403, 1999.
[78] A. M. Gonza´lez Vitores, G. E. Duro´, B. B. Fraile, and M.
A. Carrasco, “Prognostic value of the glycoprotein TAG-72
in patients with gastric cancer,” The International Journal of
Biological Markers, vol. 16, pp. 121–125, 2001.
Clinical and Developmental Immunology 9
[79] P. Allavena, M. Chieppa, P. Monti, and L. Piemonti, “From
pattern recognition receptor to regulator of homeostasis: the
double-faced macrophaqe mannose receptor,” Critical Reviews
in Immunology, vol. 24, no. 3, pp. 179–192, 2004.
[80] N. Le´de´e, R. Lombroso, L. Lombardelli et al., “Cytokines and
chemokines in follicular fluids and potential of the correspond-
ing embryo: the role of granulocyte colony-stimulating factor,”
Human Reproduction, vol. 23, no. 9, pp. 2001–2009, 2008.
[81] A. Nakashima, A. Shiozaki, S. Myojo et al., “Granulysin
produced by uterine natural killer cells induces apoptosis of
extravillous trophoblasts in spontaneous abortion,” American
Journal of Pathology, vol. 173, no. 3, pp. 653–664, 2008.
[82] D. Veljkovic Vujaklija, M. Dominovic, T. Gulic et al., “Gran-
ulysin expression and the interplay of granulysin and perforin at
the maternal-fetal interface,” Journal of Reproductive Immunol-
ogy, vol. 97, pp. 186–196, 2013.
[83] K. Kitaya, J. Yasuda, I. Yagi, Y. Tada, S. Fushiki, and H. Honjo,
“IL-15 expression at human endometrium and decidua,” Biology
of Reproduction, vol. 63, no. 3, pp. 683–687, 2000.
[84] J. N. Bulmer, L. Morrison, M. Longfellow, A. Ritson, and D.
Pace, “Granulated lymphocytes in human endometrium: his-
tochemical and immunohistochemical studies,” Human Repro-
duction, vol. 6, no. 6, pp. 791–798, 1991.
[85] S. Gordon, “Alternative activation of macrophages,” Nature
Reviews Immunology, vol. 3, pp. 23–35, 2003.
[86] O. J. Finn, “Host response in tumor diagnosis and prognosis:
importance of immunologists and pathologists alliance,” Exper-
imental and Molecular Pathology, vol. 93, pp. 315–318, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
